今日申购：禾元生物

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. is set to launch an initial public offering (IPO) on the STAR Market, aiming to raise approximately 259.95 million yuan through the issuance of 8,945,135.4 shares at a price of 29.06 yuan per share [2]. Group 1: Company Overview - The company is an innovative biopharmaceutical enterprise with a globally leading plant bioreactor technology platform [2]. - The controlling shareholder and actual controller of the company is Yang Daichang, who directly holds 15.03% of the shares, making him the largest shareholder [2]. - Through various agreements, Yang Daichang controls a total of 29.25% of the voting rights in the company [2]. Group 2: IPO Details - The company plans to raise 240 million yuan for the construction of a human albumin industrialization base, new drug research and development projects, and to supplement working capital [2]. - The expected net proceeds from the IPO, after deducting approximately 16.90 million yuan in issuance costs, are estimated to be 243.04 million yuan [2]. - The IPO is scheduled for online subscription on October 14, 2025, with a maximum subscription limit of 14,000 shares for individual investors [1].